Evaluation of62Cu labeled diacetyl-bis(N 4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer
- 133 Downloads
62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) (62Cu-ATSM) has been proposed as a generator-produced, positron-emitting tracer for hypoxic tissue imaging. From basic studies, the retention mechanism of62Cu-ATSM is considered to be closely related to cytosolic/microsomal bioreduction, a possible system for hypoxic bioreductive drug activation. In order to evaluate the characteristics of62Cu-ATSM, PET studies were performed in 4 normal subjects and 6 patients with lung cancer.62Cu-ATSM cleared rapidly from the blood with little lung uptake (0.43±0.09, uptake ratio; divided by the arterial input function) in normal subjects. Intense tumor uptake of62Cu-ATSM was observed in all patients with lung cancer (3.00±1.50). A negative correlation was observed between blood flow and flow-normalized62Cu-ATSM uptake in three of four patients. In contrast,62Cu-ATSM uptake was not related to that of18F-fluorodeoxyglucose. The negative correlation between blood flow and flow normalized62Cu-ATSM uptake suggests an enhancement of retention of62Cu-ATSM by low flow.62Cu-ATSM is a promising PET tracer for tumor imaging, which might bring new information for chemotherapeutic treatment as well as radiotherapy of hypoxic tumors.
Key words62Cu-ATSM hypoxia lung cancer 18F-FDG PET
Unable to display preview. Download preview PDF.
- 6.Linder KE, Chan YW, Cyr JE, Malley MF, Nowotnik DP, Nunn AD. Technetium-O(PnAO-(2-nitroimidazole)) [BMS181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis characterization and xanthine oxidase-catalyzed reduction.J Med Chem 37: 9–17, 1994.PubMedCrossRefGoogle Scholar
- 9.Fujibayashi Y, Taniuchi H, Wada A, Yonekura Y, Konishi J, Yokoyama A. Differential mechanism of retention of Cupyruvaldehyde-bis(N 4-methylthiosemicarbazone) (Cu-PTSM) by brain and tumor: a novel radiopharmaceutical for positron emission tomography imaging.Ann Nucl Med 9: 1–5, 1995.PubMedGoogle Scholar
- 12.Matsumoto K, Fujibayashi Y, Yonekura Y. Application of the new zinc-62/copper-62 generator: an effective labeling method for62Cu-PTSM.Nucl Med Biol 19: 39–44, 1992.Google Scholar
- 18.Fujibayashi Y, Yoshimi E, Waki A, Takahashi N, Yonekura Y. Cu-ATSM, a new tumor agent predicting ability for bioreductive drug activation.J Nucl Med 39 (suppl): 90P, 1998. [abstract]Google Scholar